These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8936349)

  • 1. A comparison of two neurologic scoring instruments for multiple sclerosis.
    Koziol JA; Frutos A; Sipe JC; Romine JS; Beutler E
    J Neurol; 1996 Mar; 243(3):209-13. PubMed ID: 8936349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.
    Rice GP; Filippi M; Comi G
    Neurology; 2000 Mar; 54(5):1145-55. PubMed ID: 10720289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial.
    Koziol JA; Lucero A; Sipe JC; Romine JS; Beutler E
    Can J Neurol Sci; 1999 Nov; 26(4):283-9. PubMed ID: 10563213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine in treatment of chronic progressive multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Lancet; 1994 Jul; 344(8914):9-13. PubMed ID: 7912347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The psychometric properties of clinical rating scales used in multiple sclerosis.
    Sharrack B; Hughes RA; Soudain S; Dunn G
    Brain; 1999 Jan; 122 ( Pt 1)():141-59. PubMed ID: 10050902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of chronic progressive multiple sclerosis with cladribine.
    Beutler E; Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1716-20. PubMed ID: 8643695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of cladribine treatment in multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
    Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing information in T2-weighted MRI scans from secondary progressive MS patients.
    Koziol JA; Wagner S; Adams HP
    Neurology; 1998 Jul; 51(1):228-33. PubMed ID: 9674807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative analysis of 2 clinical scales for clinical evaluation in multiple sclerosis: review of 302 cases].
    Felipe E; Mendes MF; Moreira MA; Tilbery CP
    Arq Neuropsiquiatr; 2000 Jun; 58(2A):300-3. PubMed ID: 10849631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
    Adams HP; Wagner S; Sobel DF; Slivka LS; Sipe JC; Romine JS; Beutler E; Koziol JA
    Eur Neurol; 1999 Jul; 42(1):52-63. PubMed ID: 10394049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
    Selby R; Brandwein J; O'Connor P
    Can J Neurol Sci; 1998 Nov; 25(4):295-9. PubMed ID: 9827230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves.
    Liu C; Blumhardt LD
    J Neurol Neurosurg Psychiatry; 1999 Oct; 67(4):451-6. PubMed ID: 10486390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients.
    Wagner S; Adams H; Sobel DF; Slivka LS; Sipe JC; Romine JS; Koziol JA
    Eur Neurol; 2000; 43(4):194-200. PubMed ID: 10828648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical scoring methods for multiple sclerosis.
    Noseworthy JH
    Ann Neurol; 1994; 36 Suppl():S80-5. PubMed ID: 8017893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. Reliability, validity and sensitivity to disease progression. Multiple Sclerosis Study Group.
    Syndulko K; Ke D; Ellison GW; Baumhefner RW; Myers LW; Tourtellotte WW
    Mult Scler; 1996 Oct; 2(3):142-56. PubMed ID: 9345379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cladribine in chronic progressive multiple sclerosis].
    Weilbach FX; Hartung HP
    Nervenarzt; 1995 Apr; 66(4):299-303. PubMed ID: 7783818
    [No Abstract]   [Full Text] [Related]  

  • 20. A questionnaire to assess neurological impairment in multiple sclerosis.
    Goodin DS
    Mult Scler; 1998 Oct; 4(5):444-51. PubMed ID: 9839306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.